Clinical Research Directory
Browse clinical research sites, groups, and studies.
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
Sponsor: M.D. Anderson Cancer Center
Summary
This randomized phase II trial studies how well haloperidol with or without lorazepam works in reducing confusion, disorientation, and inability to think or remember clearly (delirium) in patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Palliative therapy with haloperidol and lorazepam may reduce symptoms of delirium and help patients with advanced cancer live more comfortably. It is not yet known whether lorazepam may be an effective treatment for delirium when given with haloperidol.
Official title: A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
93
Start Date
2014-01
Completion Date
2028-01-01
Last Updated
2026-02-13
Healthy Volunteers
No
Conditions
Interventions
Lorazepam
3 mg by vein one time only.
Placebo
Placebo consisting of preservative free 0.9% normal saline given one time by vein.
Haloperidol decanoate
8 mg/day by vein.
Questionnaires
Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.
Locations (1)
University of Texas MD Anderson Cancer Center
Houston, Texas, United States